Axsome Therapeutics, Inc. AXSM

AXSM Company Overview

Axsome Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. The company operates primarily within the biotechnology and specialty pharmaceutical industries, targeting conditions with significant unmet medical needs in psychiatry, neurology, sleep disorders, and pain management. Axsome’s commercial and clinical strategy centers on differentiated CNS therapies that combine novel mechanisms, reformulations, and proprietary delivery technologies intended to improve efficacy, onset of action, tolerability, or patient adherence.

The company’s primary revenue drivers are its commercialized CNS products, particularly Auvelity for major depressive disorder and Sunosi for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Axsome has also advanced a broader pipeline targeting Alzheimer’s disease agitation, migraine, fibromyalgia, smoking cessation, and narcolepsy-related conditions. Founded in 2012, Axsome evolved from a development-stage biotechnology company into a commercial-stage CNS-focused pharmaceutical company following key acquisitions, regulatory approvals, and the expansion of its commercial infrastructure. The company has positioned itself as a specialized CNS innovator with a focus on rapid-acting neuropsychiatric therapies and lifecycle management of proprietary compounds.